Acute pleiotropic effects of dapagliflozin in type 2 diabetic patients with heart failure with reduced ejection fraction: a crossover trial
| Autor: | Simeoni Thomas, Fahmida Ilyas, Fiona Wollaston, Carmine G. De Pasquale, Arduino A. Mangoni, Lynette Jones, Su Ling Tee, Carla De Pasquale, Steve Stranks, T. Hecker, William Chong, Derek P. Chew, Matthew Horsfall, Joseph B. Selvanayagam, A. Swan |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
Ambulatory blood pressure Short Communication Acute effects Short Communications Diastole chemistry.chemical_compound Hyperaemia Glucosides Internal medicine Diseases of the circulatory (Cardiovascular) system Humans Medicine Benzhydryl Compounds Dapagliflozin Heart Failure Cross-Over Studies Ejection fraction Troponin T business.industry Stroke Volume HFrEF Blood Pressure Monitoring Ambulatory medicine.disease Crossover study Diabetes Mellitus Type 2 chemistry RC666-701 Heart failure Quality of Life Cardiology Mechanism medicine.symptom Cardiology and Cardiovascular Medicine business |
| Zdroj: | ESC Heart Failure ESC Heart Failure, Vol 8, Iss 5, Pp 4346-4352 (2021) |
| ISSN: | 2055-5822 |
| DOI: | 10.1002/ehf2.13553 |
| Popis: | Aims This study aimed to explore the rapid effects of dapagliflozin in heart failure with reduced ejection fraction (HFrEF). Methods and results We studied the functional, echocardiographic, electrophysiological, lung ultrasound, ambulatory blood pressure (BP), microvascular and macrovascular function, and biochemical effects of 2 week treatment with dapagliflozin in 19 type 2 diabetic HFrEF patients in a double‐blind, crossover, placebo‐controlled trial. Dapagliflozin had no significant effect on clinical, functional, or quality of life parameters. Dapagliflozin reduced systolic BP [114 (105, 131) vs. 106 (98, 113) mmHg, P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text